Arca
Skip to content
Tools
Tools

Label Changes: Jaypirca (pirtobrutinib)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Jaypirca label DailyMed has published, from Eli Lilly and Company, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 10
  • Sections changed, version 14 to 16: 9

What changed from version 14 to version 16

Mar 25, 2026 to Oct 19, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 42 words added
  2. Dosage and administrationChanged · 6 words added, 1 removed
  3. Warnings and precautionsChanged · 39 words added, 28 removed
  4. Adverse reactionsChanged · 651 words added, 50 removed
  5. Use in specific populationsChanged · 13 words added, 19 removed
  6. Clinical pharmacologyChanged · 18 words added, 14 removed
  7. Clinical studiesChanged · 633 words added, 14 removed
  8. Patient counseling informationChanged · 5 words added, 5 removed
  9. Patient informationChanged · 94 words added, 110 removed

Indications and usage

Changed42 words added
3 unchanged lines
This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion
JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.

Dosage and administration

Changed6 words added, 1 removed
4 unchanged lines
Swallow tablets whole with water. Do not cut, crush, or chew tablets.
Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food [see Clinical Pharmacology (12.3)].
If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.
10 unchanged lines
2.3 Dosage Modifications for Patients with Severe Renal Impairment
For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA [see Use in Specific Populations (8.76), Clinical Pharmacology (12.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).
2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors
3 unchanged lines

Warnings and precautions

Changed39 words added, 28 removed
1 unchanged line
5.1 Infections
Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. Across all clinical trials, Grade 3 or higher infections occurred in 2523% of 7041153 patients, most commonly pneumonia (2013%), with fatal infections occurring in 54.3% of patients. Sepsis occurred in 64.8% of patients and febrile neutropenia in 3.83%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 3224% of patients, with fatal infections occurring in 85%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, Pneumocystis jirovecii pneumonia and fungal infection [see Adverse Reactions (6.1)].
Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.2 Hemorrhage
Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 23.61% of 7041153 patients treated with JAYPIRCA across all clinical trials, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients. Bleeding of any grade, excluding bruising and petechiae, occurred in 1618% of patients [see Adverse Reactions (6.1)].
Major hemorrhage occurred in 01.68% of patients taking JAYPIRCA without antithrombotic agents and 21.03% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.
1 unchanged line
JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.
Across all clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (2726%), decreased platelets (139%), and decreased hemoglobin (119%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 1514% of patients and Grade 4 decreased platelets developed in 64.3% of patients [see Adverse Reactions (6.1)].
Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.4 Cardiac Arrhythmias
Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.41% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.6% of 7041153 patients across all clinical trials [see Adverse Reactions (6.1)]. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.43% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.
Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].
5.5 Second Primary Malignancies
Second primary malignancies, including non-skin carcinomas, developed in 910% of 7041153 patients treated with JAYPIRCA monotherapy across all clinical trials. The most frequent malignancy was non-melanoma skin cancer, reported in 4.49% of 7041153 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.
5.6 Hepatotoxicity, Including Drug-Induced Liver Injury
4 unchanged lines

Adverse reactions

Changed651 words added, 50 removed
9 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.
The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 7041153 patients with hematologic malignancies in the BRUIN and thefour BRUIN-CLL-321clinical studies. Among these 7041153 patients, the median duration of exposure was 1218 months; 6576% were exposed for at least 6 months and 5066% were exposed for at least one year.
In this pooled safety population, the most common (≥ 30%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (54%), decreased hemoglobin (43%), decreased leukocytes (32%), fatigue (31%), decreased platelets (31%), decreased lymphocyte count (31%), and calcium decreased (30%)
In this pooled safety population, the most common (≥ 30%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (56%) and decreased hemoglobin (38%).
Mantle Cell Lymphoma
6 unchanged lines
Table 2 summarizes select adverse reactions in BRUIN.
Table 2: Adverse Reactions (≥ 10%) in Patients with MCL Who Received JAYPIRCA in BRUIN
| JAYPIRCA 200 mg once daily
3 unchanged lines
c includes 1 fatality from hemorrhage.
Adverse Reactions a | All Grades (%) | Grade 3- or 4 (%)
General Disorders
27 unchanged lines
Table 3 summarizes laboratory abnormalities in BRUIN.
Table 3: Select Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA in BRUIN
a The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.
25 unchanged lines
The most common adverse reactions (≥ 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache. Table 4 summarizes select adverse reactions for patients treated on BRUIN.
Table 4: Adverse Reactions (≥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN
| JAYPIRCA 200 mg once daily
N = 110
Adverse Reactions a | All Grades (%) | Grade 3- or 4 (%)
a Each term listed includes other related terms.
52 unchanged lines
Table 5 summarizes laboratory abnormalities in BRUIN.
Table 5: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA in BRUIN
Laboratory Abnormality | JAYPIRCAa 200 mg once daily
16 unchanged lines
**Lymphocytosis: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased ≥ 50% from baseline and a post-baseline value ≥ 5,000/μL) occurred in 64% of CLL/SLL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 1.1 weeks, and the median duration was 19 weeks.
BRUIN CLL-321
The safety of JAYPIRCA was evaluated in BRUIN CLL-321, a randomized, multicenter, open-label active control trial [see Clinical Studies (14.2)]. The trial enrolled patients with relapsed or refractory CLL/SLL who were previously treated with a covalent BTK inhibitor. The trial required a platelet count ≥ 50 x 109/L, absolute neutrophil count ≥ 0.75 x 109/L, and an estimated creatinine clearance ≥ 30 mL/min. The trial excluded patients with significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, or major bleeding on a prior covalent BTK inhibitor.
2 unchanged lines
Serious adverse reactions occurred in 47% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 3% of patients were pneumonia (21%), COVID-19 (5%), and sepsis (3.4%). Fatal adverse reactions within 30 days of the last dose of JAYPIRCA occurred in 8% of patients, most commonly due to infections (7%), COVID-19 (5%) and pneumonia (3.4%).
Adverse reactions led to permanent discontinuation of JAYPIRCA in 17% of patients, dose reductions in 10%, and treatment interruption in 51%. Adverse reactions which resulted in dose reductions of JAYPIRCA in > 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in > 5% of patients included pneumonia, neutropenia, hemorrhage and COVID-19. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in > 1% of patients included pneumonia, COVID-19, neutropenia, anemia, and cardiac arrythmiasarrhythmias.
The most common adverse reactions (≥ 20%), excluding laboratory terms, were pneumonia and upper respiratory tract infections. Table 6 summarizes select adverse reactions for patients treated on BRUIN CLL-321.
Table 6: Adverse Reactions (≥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA (in BRUIN CLL-321)
a Each term listed includes other related terms.
3 unchanged lines
N = 116 | N = 109
Adverse Reactions a | All Grades (%) | Grade 3- or 4 (%) | All Grades (%) | Grade 3- or 4 (%)
Pneumonia | 28b | 16 | 16b | 11
17 unchanged lines
Table 7 summarizes laboratory abnormalities in BRUIN CLL-321.
Table 7: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA (in BRUIN CLL-321)
a The denominator used to calculate the rate varied from 113 to 114 in the JAYPIRCA arm and from 29 to 31 for bendamustine plus rituximab, and 75 for idelalisib plus rituximab, based on the number of patients with a baseline value and at least one posttreatment value.
11 unchanged lines
Bilirubin increased | 21 | 0.9 | 21 | 1
BRUIN CLL-313
The safety of JAYPIRCA was evaluated in the BRUIN CLL-313 trial, a randomized, multicenter, open-label, active control trial [see Clinical Studies (14.2)]. The trial enrolled patients with treatment naïve CLL/SLL without deletion of chromosome 17p13.1 (del 17p). The trial required a platelet count ≥ 75 × 109/L, absolute neutrophil count ≥ 0.75 × 109/L, and creatinine clearance ≥ 40 mL/min). The trial excluded patients with 17p deletion, significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, active uncontrolled autoimmune cytopenias, or an active second malignancy.
The trial enrolled 282 patients who were randomized 1:1 to receive JAYPIRCA given orally once daily at a dose of 200 mg until disease progression or unacceptable toxicity or bendamustine in combination with a rituximab product (BR) for 6 cycles. One hundred forty patients received JAYPIRCA, and 132 patients received BR.
The median duration of treatment with JAYPIRCA was 32 months with 92% of patients on treatment for greater than 24 months.
Serious adverse reactions occurred in 28% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 3% of patients included pneumonia (5%). Fatal adverse reactions within 30 days of the last dose of JAYPIRCA occurred in 1 (0.7%) patient, due to septic shock.
Adverse reactions led to permanent discontinuation of JAYPIRCA in 4.3% of patients, dose reductions in 3.6%, and treatment interruption in 35%. Adverse reactions which resulted in dose reductions of JAYPIRCA in > 1% of patients included pruritus. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in > 5% of patients included COVID-19.
The most common adverse reactions (≥ 20%), excluding laboratory terms, were upper respiratory tract infections, rash, and COVID-19. Table 8 summarizes select adverse reactions for patients treated on BRUIN CLL-313.
Table 8: Adverse Reactions (≥ 10%) in Patients with Previously Untreated CLL/SLL Without 17p Deletion Who Received JAYPIRCA in BRUIN CLL-313
a Each term listed includes other related terms.
b Includes COVID-19 pneumonia.
c Includes bronchitis, respiratory tract infection, influenza, influenza like illness, respiratory tract infection bacterial.
| JAYPIRCA | Bendamustine + Rituximab Product
N = 140 | N = 132
Adverse Reactions a | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%)
Infections
Upper respiratory tract infections | 27 | 2.1 | 8 | 0
COVID-19 | 21b | 0.7 | 10b | 2.3
Respiratory tract infection | 11c | 1.4 | 6c | 0
Urinary tract infection | 10 | 1.4 | 1.5 | 0.8
Skin and Subcutaneous Disorders
Rash | 22 | 0.7 | 26 | 2.3
General Disorders
Hemorrhage | 12 | 0.7 | 1.5 | 0
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal pain | 17 | 0.7 | 8 | 0.8
Arthralgia | 12 | 0.7 | 1.5 | 0
Injury
Bruising | 11 | 0 | 0 | 0
Vascular Disorder
Hypertension | 10 | 4.3 | 4.5 | 3.0
Clinically relevant adverse reactions in <10% of patients who received JAYPIRCA include pneumonia and headache.
Table 9 summarizes laboratory abnormalities in BRUIN CLL-313.
Table 9: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Previously Untreated CLL/SLL Without 17p Deletion Who Received JAYPIRCA in BRUIN CLL-313
a The denominator used to calculate the rate was 140 in the JAYPIRCA arm and varied from 128 to 129 for the BR arm, based on the number of patients with a baseline value and at least one post-treatment value.
Laboratory Abnormality | JAYPIRCA a | Bendamustine + Rituximab Product a
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%)
Hematology
Neutrophil count decreased | 48 | 14 | 78 | 45
Hemoglobin decreased | 24 | 6 | 34 | 9
Chemistry
Bilirubin increased | 30 | 5 | 9 | 2.3
ALT increased | 27 | 2.9 | 23 | 0
Sodium increased | 20 | 0 | 13 | 0

Use in specific populations

Changed13 words added, 19 removed
20 unchanged lines
8.5 Geriatric Use
Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older [see Clinical Studies (14.1)]. Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than 65 years of age to determine whether older patients respond differently from younger adult patients. Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in BRUINfour andclinical BRUIN-321studies, 220480 (6561%) were 65 years of age and older and 78165 (3321%) were 75 years and older [see Clinical Studies (14.2)]. No overall differences in effectiveness were observed between younger and older patients.
In the pooled safety population in patients with hematologic malignancies in BRUIN and BRUIN CLL-321, 467720 (6662%) were 65 years of age and older, while 181266 (2623%) were 75 years of age and older. Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.
8.6 Renal Impairment
Severe renal impairment (eGFR15eGFR 15-29 mL/min) increases pirtobrutinib exposure [see Clinical Pharmacology (12.3)]. Reduce the JAYPIRCA dosage in patients with severe renal impairment [see Dosage and Administration (2.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.
8.7 Hepatic Impairment
1 unchanged line

Clinical pharmacology

Changed18 words added, 14 removed
8 unchanged lines
The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and Cmax increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4 times the approved recommended dosage) and once daily doses ranging from 25 – 300 mg (0.125 to 1.5 times the recommended dosage). Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages.
Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and Cmax of pirtobrutinib were 9270597100 h*ng/mL (3935.5%) and 65036690 ng/mL (2524%), respectively. The geometric mean (CV%) AUC0-24 and Cmax of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively.
Absorption
3 unchanged lines
Distribution
The mean apparent central volume of distribution of pirtobrutinib is 3435.24 L. Human protein binding of pirtobrutinib is 96% and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79.
Elimination
The effective half-life of pirtobrutinib is approximately 2019.9 hours and the mean (CV%) apparent clearance is 21.0598 L/h (3532.71 %).
Metabolism
3 unchanged lines
Specific Populations
There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 22 –to 95 years), sex, race/ethnicity (White 8481%, Asian 811%), body weight (range 35.7 –to 152154 kg), mild (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or total bilirubin > 1 to 1.5 × ULN and any AST), moderate (total bilirubin > 1.5 to 3 × ULN and any AST), or severe (total bilirubin > 3 × ULN and any AST) hepatic impairment. The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown.
Patients with Renal Impairment
18 unchanged lines

Clinical studies

Changed633 words added, 14 removed
3 unchanged lines
The median age was 71 years (range: 46 to 88 years); 79% were male; 78% were White, 14% Asian, 1.7% Black or African American. Seventy-eight percent of patients had the classic/leukemic variant of MCL, 12% had pleomorphic MCL, and 11% had blastoid MCL. The simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) score was low in 15%, intermediate in 59%, and high in 26% of patients. Patients received a median number of 3 prior lines of therapy (range: 1 to 9) with 93% having received 2 or more prior lines. All received 1 or more prior lines of therapy containing a BTK inhibitor; other prior therapies included chemoimmunotherapy in 88%, HSCT in 20%, lenalidomide in 18%, and CAR-T therapy in 9%. The most common prior BTK inhibitors received were ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%). Patients may have received more than one prior BTK inhibitor; 83% of patients discontinued the last BTK inhibitor for refractory or progressive disease, 10% discontinued for toxicity, and 5% discontinued for other reasons.
Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2014 Lugano criteria. Efficacy results are shown in Table 810. Additionally, the Kaplan-Meier estimate for the DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).
Table 810: Efficacy Results per IRC in Patients with MCL Previously Treated with a BTK Inhibitor in BRUIN
CI, confidence interval; CR, complete response; DOR, duration of response; PR, partial response; NE, not estimable.
17 unchanged lines
The median age was 68 years (range: 41 to 88 years); 69% were male; 89% were White, 4.6% Black or African American, 1.9% Asian and 1.9% were Hispanic or Latino. Baseline ECOG performance status was 0 or 1 in 91% of patients and 48% of patients had Rai stage III or IV disease. Among those patients with central testing available, 42% (37 of 88 patients) had a C481 BTK mutation, 54% (43 of 79 patients) had 17p deletion and/or TP53 mutation, 93% (77 of 83 patients) had unmutated IGHV, and 22% (16 of 72 patients) had 11q deletion. Patients received a median number of 5 prior lines of therapy (range: 2 to 11). The most common prior BTK inhibitors received were ibrutinib (97%), acalabrutinib (9%), and zanubrutinib (0.9%). Seventy-seven percent of patients discontinued the last BTK inhibitor for refractory or progressive disease, 13% discontinued for toxicity, and 10% discontinued for other reasons.
Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2018 iwCLL criteria. Efficacy results are shown in Table 9 -11. The median time to response was 3.7 months (range: 1.7, 27.9 months).
Table 911: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor and a BCL-2 inhibitor in BRUIN
CI, confidence interval; PR, partial response.
7 unchanged lines
Median DOR, months (95% CI) | 12.2 (9.3, 14.7)
BRUIN- CLL-321
The efficacy of JAYPIRCA in patients with covalent BTK-inhibitor pretreated CLL/SLL was evaluated in a randomized, open-label, active-controlled study (BRUIN- CLL-321, NCT 04666038NCT04666038).
The trial randomized 238 patients who were previously treated for CLL/SLL, including a covalent BTK inhibitor. Patients previously treated with a non-covalent BTK inhibitor were not permitted. Patients were randomized in a 1:1 ratio to receive either:
3 unchanged lines
Randomization was stratified by 17p deletion status and receipt of prior venetoclax treatment. Of the 238 patients randomized, 119 were assigned to JAYPIRCA monotherapy, 82 to IR, and 37 to BR. The median age was 67 years (range: 42 to 90 years); 70% were male; 81% were White, 12% Asian, 2.5% Black or African American, and 4.2% were Hispanic or Latino. Baseline ECOG performance status was 0 or 1 in 93% of patients and 46% of patients had Rai stage III or IV disease. Forty four percent had 17p deletion and/or TP53 mutation, 69% had unmutated IGHV, and 41% had complex karyotype. Patients received a median number of 3 prior lines of therapy (range: 1 to 13); 51% had received prior BCL2-inhibitor therapy. The most common prior BTK inhibitors received were ibrutinib (87%), acalabrutinib (16%), and zanubrutinib (7%). Seventy-one percent of patients discontinued the most recent BTK inhibitor for refractory or progressive disease, 17% discontinued for toxicity, and 10% discontinued for other reasons.
The primaryEfficacy efficacywas outcomeestablished measurebased wason progression-free survival (PFS), as assessed by an Independent Review Committee (IRC) using 2018 iwCLL criteria. The median duration of follow up at the primary analysis was 6.6 months. Efficacy results for the primary analysis are presented in Table 1012 and Figure 1.
Table 1012: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor (in BRUIN CLL-321)
CI, confidence interval; HR, hazard ratio.
14 unchanged lines
At an updated analysis with a median follow-up time of 19.8 months, 38 patients (32%) in the JAYPIRCA arm and 32 patients (27%) in the investigator's choice arm died. The unadjusted HR for overall survival (OS) was 1.09 (95% CI: 0.68, 1.75). The ORR was 48.7% (95% CI 39.5, 58.1) in the JAYPIRCA arm and 38.7% (95% CI 29.9, 48.0) in the investigator choice arm.
BRUIN CLL-313
The efficacy of JAYPIRCA was evaluated in a randomized, open-label, active-controlled study in 282 patients with treatment naïve CLL/SLL without 17p deletion (del17p) (BRUIN CLL-313, NCT05023980). The trial required patients to have a platelet count ≥ 75 x 109/L, absolute neutrophil count ≥ 0.75 x 109/L, and an estimated creatinine clearance ≥ 40 mL/min. The trial excluded patients with significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, active uncontrolled auto-immune cytopenia, or an active second malignancy.
Patients were randomized 1:1 ratio to receive:
JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity, or
Bendamustine plus a rituximab product (BR): Bendamustine 90 mg/m2 intravenously (Day 1 and 2 of each 28-day cycle), in combination with a rituximab product (375 mg/m2 intravenously on Day 1 of Cycle 1, then 500 mg/m2 on Day 1 of subsequent cycles), for up to 6 cycles.
Crossover to JAYPIRCA monotherapy was permitted for patients in the BR arm after confirmed disease progression. Eighteen out of the 141 patients in the BR arm crossed over and received JAYPIRCA therapy.
Randomization was stratified by immunoglobulin variable region heavy chain (IGHV) mutational status and by Rai stage status.
Of the 282 patients randomized, 141 were assigned to JAYPIRCA monotherapy and 141 to BR. The median age was 66 years (range: 29 to 88); 61% were male; 73% were White, 23% Asian, 0.4% Black or African American; 9% were Hispanic or Latino, 88% not Hispanic or Latino, 2.8% not reported or unknown. Baseline ECOG performance status was 0 or 1 in 94% of patients and 34% of patients had Rai stage III or IV disease. Among randomized patients, 57% had unmutated IGHV, and 10% had complex karyotype.
Efficacy was established based on progression-free survival (PFS), as assessed by an Independent Review Committee (IRC). The estimated median time of follow-up was 28 months. Efficacy results for the primary analysis are presented in Table 13 and Figure 2.
Table 13: Efficacy Results per IRC in Patients with Previously Untreated CLL/SLL Without 17p Deletion in BRUIN CLL-313
Parameter a | JAYPIRCA 200 mg once daily (N = 141) | Bendamustine + Rituximab Product (N = 141)
CI, confidence interval; CR, complete response; CRi, complete remission with incomplete hematologic recovery; HR, hazard ratio; NE, not estimable; nPR, nodular partial remission; ORR, overall response rate; PFS, progression-free survival; PR, partial response.
a Efficacy was assessed using the 2018 International Workshop for Chronic Lymphocytic Leukemia (iwCLL) guidelines.
b Based on Kaplan-Meier estimation.
c Based on stratified Cox proportional hazards model.
d 2-sided p-value based on stratified log-rank test.
e Defined as CR + CRi + nPR + PR. No patients had CRi or nPR as best response.
Progression-free Survival | |
Number of Events, n (%) | 13 (9) | 48 (34)
Disease Progression | 13 (9) | 40 (28)
Death | 0 | 8 (6)
Median PFS (95% CI), months b | NE (NE, NE) | 33.5 (32.7, NE)
HR (95% CI) c | 0.20 (0.11, 0.37)
P-value d | <0.0001
Overall Response Rate e | |
ORR, n (%) | 133 (94) | 114 (81)
(95% CI, %) | (89, 98) | (73, 87)
CR, n | 19 (13) | 29 (21)
PR, n | 114 (81) | 85 (60)
Figure 2 Kaplan-Meier Curve of IRC-Assessed PFS in Patients with Previously Untreated CLL/SLL Without 17p Deletion in BRUIN CLL-313
At the time of the primary PFS analysis, with an estimated median follow-up for overall survival (OS) of 32 months, the median OS was not reached in either arm with a total of 13 deaths: 3 deaths (2.1%) in the JAYPIRCA arm and 10 deaths (7.1%) in the BR arm.

Patient counseling information

Changed5 words added, 5 removed
21 unchanged lines
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Copyright © 2023, 20252026, Eli Lilly and Company. All rights reserved.
Pat.: www.lilly.com/patents
JAY-0006-USPI-20251216
JAY-0007-USPI-20261002

Patient information

Changed94 words added, 110 removed
This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 1210/20252026
PATIENT INFORMATION JAYPIRCA ® (JAY-PIHR-KAA) pirtobrutinib tablets
What is JAYPIRCA? JAYPIRCA is a prescription medicine used to treat adults with: mantle cell lymphoma (MCL) that has come back (relapsed) or did not respond to previous treatment (refractory) and who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine. relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) thatwho hashave comepreviously backbeen ortreated didfor nottheir respondcancer towith previousa treatmentcovalent andBTK inhibitor medicine. CLL or SLL who have alreadynot previously been treated withfor atheir BTKcancer inhibitorand forwho theirhave cancerno known 17p deletion.
It is not known if JAYPIRCA is safe and effective in children.
Before taking JAYPIRCA, tell your healthcare provider about all of your medical conditions, including if you: have an infection or have been advised that you are at increased risk of infection have had recent surgery or plan to have surgery. Your healthcare provider may stop JAYPIRCA for any planned medical, surgical, or dental procedure. have bleeding problems or are taking a blood thinner medicine have or had heart rhythm problems have high blood pressure have a history of other cancers including skin cancer have kidney problems have liver problems are pregnant or plan to become pregnant. JAYPIRCA can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before starting treatment with JAYPIRCA. You should useUse effective birth control (contraception) during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with JAYPIRCA. are breastfeeding or plan to breastfeed. It is not known if JAYPIRCA passes into your breast milk. Do not breastfeed during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking JAYPIRCA with certain other medicines may affect how JAYPIRCA or the other medicines work and can cause side effects.
How should I take JAYPIRCA? Take JAYPIRCA exactly as your healthcare provider tells you. Do not change your dose or stop taking JAYPIRCA unless your healthcare provider tells you to do so. Take JAYPIRCA 1 time each day at about the same time each day. Take JAYPIRCA with or without food. Swallow JAYPIRCA whole with water. Do not cut, crush, or chew the tablets. If you miss a dose of JAYPIRCA, take it as soon as you remember on the same day. If it has been more than 12 hours from the time you usually take JAYPIRCA, skip the missed dose, and take your next dose on the next day at your usual time.
What are the possible side effects of JAYPIRCA? JAYPIRCA can cause serious side effects, including: Infections can happen during treatment with JAYPIRCA. These infections can be serious and may lead to death. Your healthcare provider may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you develop feverany signs or symptoms of infection, including: fever chills, weakness, flu-like symptoms, or any other signs of infection during treatment with JAYPIRCA. Bleeding problems (hemorrhage). Bleeding problems can happen during treatment with JAYPIRCA and can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including: blood in your stools or black stools (looks like tar) pink or brown urine unexpected bleeding, or bleeding that is severe or you cannot control vomit blood or vomit blood that looks like coffee grindsgrounds cough up blood or blood clots increased bruising dizziness weakness confusion changes in your speech headache that lasts a long time Decrease inDecreased blood cell counts. Decrease in blood cell, countsincluding (white blood cells, platelets, and red blood cells) are common with JAYPIRCA, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with JAYPIRCA. Heart rhythm problems. Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with JAYPIRCA. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your healthcare provider if you develop any of the following signs or symptoms: fast or irregular heartbeat (palpitations) dizziness fainting chest discomfort shortness of breath Second primary cancers. New cancers have happened in people during treatment with JAYPIRCA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with JAYPIRCA. Use sun protection when you are outside in sunlight. Liver Problems. Liver problems, whichthat may be severe or, life-threatening, or lead to death, can happen in people treated with JAYPIRCA. Your healthcare provider will do blood tests to check your liver before and during treatment with JAYPIRCA. Tell your healthcare provider or get medical help right away if you havedevelop any signs of liver problems, including: stomach pain or discomfort, dark-colored urine, or yellow skin and eyes Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with JAYPIRCA if you develop severe side effects. The most common side effects of JAYPIRCA include:
Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with JAYPIRCA if you develop severe side effects. The most common side effects of JAYPIRCA include:
decreased white blood cell count decreased red blood cell count tiredness | decreased platelet count decreased calcium |
decreased white blood cell counts | decreased red blood cell counts
These are not all the possible side effects of JAYPIRCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
2 unchanged lines
General information about the safe and effective use of JAYPIRCA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use JAYPIRCA for a condition for which it was not prescribed. Do not give JAYPIRCA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JAYPIRCA that is written for health professionals.
What are the ingredients in JAYPIRCA? Active ingredient: pirtobrutinib Inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. The tablet film coating contains FD&C Blue #2, hypromellose, titanium dioxide, and triacetin. Marketed by Lilly USA, LLC, Indianapolis, IN 46285, USA JAYPIRCA is a registered trademark of Eli Lilly and Company. Copyright © 2023, 20252026, Eli Lilly and Company. All rights reserved. JAY-00050007-PPI-2025120320261002 For more information, go to www.jaypirca.com or call 1-800-LillyRx (1-800-545-5979).

Unchanged: Dosage forms and strengths, Contraindications, Drug interactions, Description, Nonclinical toxicology, How supplied, Package label.

Every version

10 versions of set bd551845-0878-49a4-860f-839b83f6b801, newest first.
VersionPublished on DailyMedCompareSPL file
16Oct 19, 2026Shown belowDownload .zip
14Mar 25, 2026With version 13Download .zip
13Dec 15, 2025With version 11Download .zip
11Mar 21, 2025With version 9Download .zip
9Nov 15, 2024With version 8Download .zip
8Aug 22, 2024With version 6Download .zip
6Jun 17, 2024With version 4Download .zip
4Mar 6, 2024With version 3Download .zip
3Dec 15, 2023With version 2Download .zip
2Feb 10, 2023First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.